A POC Clinical Trial for PTSD with a First-In-Class Vasopressin 1a Receptor Antagonist

Abstract

In this reporting period, year 1 of the project, the major milestones met included obtaining approval from the responsible local Institutional Review Board (IRB) and the Human Research Protections Office (HRPO); the hiring and training of personnel that will work on the clinical trial; and the acquisition of equipment and methods set-up. In the second year of the project, the major objective will be to recruit and enroll subjects to participate in the clinical study that will test the effect of SRX246, a first-in-class vasopressin 1a receptor antagonist, as a potential new treatment for PTSD.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2016
Accession Number
AD1034589

Entities

People

  • JoAnn Difede
  • Neal Simon

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Acquisition
  • Biomedical Research
  • Clinical Trials
  • Data Analysis
  • Data Management
  • Electronic Mail
  • Employment
  • Health Services
  • Institutional Review Board
  • Medical Personnel
  • Personnel Management
  • Physicians
  • Pituitary And Hypothalamic Hormones And Analogues
  • Professional Development
  • Public Relations
  • Quality Of Life
  • Training

Fields of Study

  • Medicine

Readers

  • Clinical Trial Research.